EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial



The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial



Neuropsychobiology 54(3): 195-200



Background: Pramipexole is a D3 dopaminergic agonist that has shown a major effect on both sensory and motor manifestations of restless legs syndrome (RLS) in long-term trials. No data regarding the acute effect of low doses of pramipexole have been reported. Objective: To evaluate the acute effect of a low dosage of pramipexole (0.125 mg) on sensory symptoms and motor signs of RLS and on the macro- and microstructure of sleep. Methods: We initially recruited 13 patients affected by severe idiopathic RLS and included 10 of them in our study. For 2 consecutive nights the selected patients were evaluated. Pramipexole 0.125 mg was administered before the second night at 9: 00 p. m. A visual analog scale was used to assess the sensory symptoms of RLS. The motor manifestations of RLS and the architecture of sleep were analyzed by polysomnography. Results: After the acute administration of pramipexole, we observed a significant improvement of the sensory symptoms and motor signs of RLS. Several sleep macrostructure and microstructure parameters improved as well. Conclusions: Our results suggest that low doses of pramipexole are effective in reducing sensory symptoms and motor signs of RLS, even after the first administration. Copyright (c) 2006 S. Karger AG, Basel.

(PDF emailed within 0-6 h: $19.90)

Accession: 013022161

Download citation: RISBibTeXText

PMID: 17314491

DOI: 10.1159/000099947



Related references

Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology 50(1): 65-70, 2004

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Medicine 9(8): 865-873, 2008

Long-term open-label study of pramipexole in patients with primary restless legs syndrome. Journal of the Neurological Sciences 294(1-2): 62-66, 2010

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Movement Disorders 21(9): 1404-1410, 2006

Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 27(4): 674-682, 2004

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet. Neurology 10(8): 710-720, 2011

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Medicine 9(5): 537-541, 2008

Rotigotine transdermal patch improves quality of life in patients with idiopathic restless legs syndrome - 24 month results from a multi-national multi-centre, open-label, follow-up trial. 2007

Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet. Neurology 12(12): 1141-1150, 2014

Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial. Sleep 23(3): 349-354, 2000

Antibiotic therapy may improve idiopathic restless legs syndrome: prospective, open-label pilot study of rifaximin, a nonsystemic antibiotic. Sleep Medicine 11(4): 427-427, 2010

Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52(5): 938-943, 1999

Improvements in daytime symptoms in patients with restless legs syndrome - 24 months results from a multinational, open-label trial with the rotigotine transdermal system. 2007

Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Medicine 12(1): 34-40, 2011

Pramipexole: new use for an old drug - the potential use of pramipexole in the treatment of restless legs syndrome. Neuropsychiatric Disease and Treatment 2(4): 393-405, 2006